Study of BBI-02 Capsules in healthy subjects and subjects with atopic dermatitis

Brickell Biotech, Inc is starting a new clinical trial of A Safety, Tolerability and Preliminary Efficacy Study of BBI-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis.

BBI-02 is an orally-available, potent and selective DYRK1A inhibitor.

This is a randomized, placebo controlled, double blind study in healthy subjects and subjects with atopic dermatitis that is designed to assess the safety and tolerability of BBI-02 capsules at single and multiple ascending doses. Safety will be assessed through vital signs, ECG, adverse events and safety laboratory tests. Pharmacokinetic and pharmacodynamic information will also be collected.

The clinical trial started in May 2022 and will continue throughout October 2023.

The number of participants with treatment-emergent adverse events will be primary outcome measure. Number of participants with adverse events, abnormal vital signs, abnormal ECG readings and abnormal laboratory test results.

The contacts and locations are the Syneos Health Quebec, Montréal, Quebec, Canada. For more details: https://ichgcp.net/clinical-trials-registry/NCT05382819.